DUBLIN
Research and Markets (http://www.researchandmarkets.com/research/5fxhnt/communityacquired) has announced the addition of Decision Resources, Inc’s new report “Community-Acquired Bacterial Pneumonia” to their offering.
The community-acquired bacterial pneumonia (CABP) market is highly crowded and genericized; nevertheless, it has important unmet needs for new therapies that are active against key drug-resistant pathogens and that can demonstrate efficacy in the moderate to severe CABP population. Although the majority of CABP patients are treated in the outpatient setting, the inpatient setting represents more than half of the CABP market and will be the area of highest commercial growth over the 2010-2020 period. Key drivers of the CABP inpatient segment include the uptake of marketed and emerging antibiotic brands and the anticipated increase in disease severity among hospitalized patients.
Key Topics Covered:
– Executive Summary
– 1 Etiology and Pathophysiology
– 2 Epidemiology and Patient Populations
– 3 Current Therapies and Medical Practice
– 4 Unmet Needs
– 5 Emerging Therapies
– Overview
– Future Positioning of Key Competitors
– Drug Development and Regulatory Hurdles
– Oxazolidinones
– Overview
– Mechanism of Action
– Radezolid
– Macrolides and Related Agents
– Overview
– Mechanism of Action
– Solithromycin
– Quinolones
– Overview
– Mechanism of Action
– Nemonoxacin
– Delafloxacin
– JNJ-Q2
– Zabofloxacin
– Streptogramins
– Overview
– Mechanism of Action
– NXL-103
– 6 Market Outlook
– Appendix A Bibliography Community Acquired Bacterial Pneumonia
– Appendix B Market Forecast Methodology
– Appendix C Experts Interviewed Community Acquired Bacterial Pneumonia
– Tables and Figures
For more information visit http://www.researchandmarkets.com/research/5fxhnt/communityacquired
Source: Decision Resources, Inc
CONTACT
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices, Pharmaceuticals
